Trial Profile
A simplified HAART regimen with lopinavir/ritonavir in HIV infected patients commencing treatment for concurrent hepatitis C infection.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Aug 2011
Price :
$35
*
At a glance
- Drugs Lopinavir/ritonavir (Primary) ; Emtricitabine/tenofovir disoproxil fumarate; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C; HIV infections
- Focus Adverse reactions
- Acronyms KAMON-2
- 11 Aug 2011 New trial record